Download Image
    
Share
  
Post
Crizanlizumab for COVID-19
2 studies with 463 patients
Hospital Icon Control
Hospital Icon Crizanlizumab Serious Outcome Risk
COVID-19 Crizanlizumab studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -29% Mortality -33% RCTs -29% Late -29% Favorscrizanlizumab Favorscontrol
Aug 31
2023
 Solomon et al., Circulation, doi:10.1161/CIRCULATIONAHA.123.065190 Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
33% higher mortality (p=0.24) and 43% worse results (p=0.16). RCT 422 hospitalized COVID-19 patients showing no significant difference in mortality or organ support-free days with crizanlizumab, a P-selectin inhibitor. There was a trend towards increased mortality with crizanlizumab. The study was s..
Dec 31
2021
 Leucker et al., JACC: Basic to Translational Science, doi:10.1016/j.jacbts.2021.09.013 Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19
35% lower hospital discharge (p=0.16). RCT 54 hospitalized COVID-19 patients showing crizanlizumab treatment reduced soluble P-selectin levels, increased D-dimer levels, and decreased prothrombin fragment 1.2 compared to placebo. There were no significant differences in inflam..